About: Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
Creator	Autmizguine, Julie Dionne, Audrey Fournier, Anne Le, Cathie-Kim Poupart, Steffany Turgeon, Jean Amarie Meloche-Dumas, Lé Dahdahid, Nagib
Source	Medline; PMC
abstract	INTRODUCTION: Kawasaki disease (KD) can be associated with concomitant viral or bacterial infections. Children with persistent or recurrent fever 36 hours after the end of intravenous immunoglobulin (IVIG) are considered to be resistant to treatment and are at increased risk for coronary complications. Although concomitant infection does not affect coronary outcome, it is unknown how it influences the response to IVIG treatment. METHODOLOGY: Retrospective cohort study between 2008 and 2016 in a tertiary pediatric university hospital, including 154 children, of which 59 (38%) had concomitant infection. RESULTS: Children with concomitant infection were more likely to have fever 48 hours after initial IVIG treatment (36% vs 20%, p = 0.05) and to be treated with a second dose (33% vs 18%, p = 0.04). Children with infection had higher C-reactive protein at the time of diagnosis (148 vs 112 mg/L, p = 0.04), and 48 hours after IVIG administration (111 vs 59 mg/L, p = 0.003). Nevertheless, there was no statistically significant difference in the prevalence of coronary complications (Z-score > 2.5) between children with and without concomitant infection (36% vs 39%, p = 0.68). CONCLUSION: Children with KD and concomitant infection are more likely to have persistent fever and elevated inflammatory markers after treatment. This association increases the likelihood of receiving a second dose of IVIG but not the risk of coronary complication. Accordingly, prospective studies to distinguish true IVIG resistance from infection induced persistent fever is warranted.
has issue date	2018-10-17(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0206001
bibo:pmid	30332473
has license	cc-by
sha1sum (hex)	e0af0e80af8fd724d1a23f90590617d72b452e1b
schema:url	https://doi.org/10.1371/journal.pone.0206001
resource representing a document's title	Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
has PubMed Central identifier	PMC6192641
has PubMed identifier	30332473
schema:publication	PLoS One
resource representing a document's body	covid:e0af0e80af8fd724d1a23f90590617d72b452e1b#body_text
is schema:about of	named entity 'PERSISTENT' named entity 'OUTCOME' named entity 'RESPONSE TO' named entity 'INCREASED RISK' named entity 'COMPLICATIONS' named entity 'HOURS' named entity 'TREATMENT' named entity 'IVIG' named entity 'Children' named entity 'IVIG' named entity 'risk' named entity 'KAWASAKI DISEASE' named entity 'RESISTANT TO' named entity 'CORONARY' named entity 'INFECTION' named entity 'ASSOCIATED WITH' named entity 'AFFECT' named entity 'DOES NOT' named entity 'INFECTION' covid:arg/e0af0e80af8fd724d1a23f90590617d72b452e1b named entity 'CONCOMITANT' named entity 'TREATMENT' named entity 'RESISTANCE TO' named entity 'PATIENTS' named entity 'KAWASAKI DISEASE' named entity 'CHILDREN' named entity 'INTRAVENOUS IMMUNOGLOBULIN' named entity 'CONCOMITANT' named entity 'VIRAL' named entity 'HOW' named entity 'IVIG' named entity 'BACTERIAL INFECTIONS' named entity 'END' named entity 'PROFILE' named entity 'UNKNOWN' named entity 'RECURRENT FEVER' named entity 'CONSIDERED' named entity 'Although' named entity 'infection' named entity 'IVIG' named entity 'infection' named entity 'intravenous immunoglobulin' named entity 'fever' named entity 'fever' named entity 'TNF alpha' named entity 'infection' named entity 'upper respiratory tract infection' named entity 'infection' named entity 'IVIG' named entity 'intravenous immunoglobulin' named entity 'infection' named entity 'infection' named entity 'pharyngitis' named entity 'sample size' named entity 'infection' named entity 'bacterial infections' named entity 'C-reactive protein' named entity 'bacterial infection' named entity 'carrier status' named entity 'antibiotics' named entity 'IVIG' named entity 'infection' named entity 'adenovirus' named entity 'viral gastroenteritis' named entity 'infection' named entity 'infection' named entity 'retrospective study' named entity 'infection' named entity 'Prospective studies' named entity 'IVIG' named entity 'infection' named entity 'IVIG' named entity 'infection' named entity 'IVIG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software